Search clinical trials for: dabrafenib

Total 172 results

Saint Petersburg State University, Russia

Recruiting

Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy

Anaplastic Thyroid Cancer

Russian Federation
Shandong University

Not yet recruiting

Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma

Ameloblastoma
Novartis Pharmaceuticals

Recruiting

Special Drug Use-results Surveillance of Tafinlar/Mekinist

BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor

Japan
Fudan University

Recruiting

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Advanced Thyroid Cancer Patients Who Received Target Therapy

China
Leiden University Medical Center
Novartis

Recruiting

NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) (NEO-ATACT)

Anaplastic Thyroid Cancer

Netherlands
Sun Yat-sen University

Not yet recruiting

Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

NSCLC | BRAF V600 Mutation | MET Exon 14 Mutation

China
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

NSCLC | Advanced Cancer | Stage IV NSCLC | BRAF V600E Mutation | Stage IIIB NSCLC
Zhejiang Cancer Hospital

Not yet recruiting

Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer

Advanced Colorectal Cancer

China
Se Jun Park

Recruiting

Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations

Cancer

Korea, Republic of
Novartis Pharmaceuticals

Recruiting

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors

United States
American Regent, Inc.

Not yet recruiting

Tralement Versus a Fixed-dose Trace Element Combination Product of Zinc, Copper, and Selenious Acid to Evaluate Product Safety in Pediatric Patients >3 to 17 Years of Age Requiring Long-term Parenteral Nutrition

Manganese Safety in Pediatric Patients
American Regent, Inc.

Not yet recruiting

Tralement Versus a Fixed-dose Trace Element Combination Product of Zinc, Copper, and Selenious Acid to Evaluate Product Safety in Adult Patients Requiring Long-term Parenteral Nutrition

Manganese Safety in Adults
Eva Marie Erfurth, MD, PhD
Novartis

Recruiting

Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma (Swecranio)

Craniopharyngioma

Sweden
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the Central Nervous System

United States
Olivia Newton-John Cancer Research Institute
The Alfred; Austin Health; Peter MacCallum Cancer Centre, Australia; Royal Brisbane... and other collaborators

Recruiting

A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) (I-FIRST)

Thyroid Cancer

Australia
MelanomaPRO, Russia
Novartis

Recruiting

pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE (RATIONALE)

Melanoma | Melanoma Stage IV | Melanoma Stage III

Russian Federation
Helsinki University Central Hospital

Recruiting

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE)

Solid Tumor | Advanced Cancer | Haematological Malignancy

Finland
Kafrelsheikh University
Ministry of Health, Saudi Arabia

Not yet recruiting

Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19

Tuberculosis

Egypt, Saudi Arabia
Novartis Pharmaceuticals

Recruiting

Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma. (LEAD Melanoma)

Melanoma

Turkey
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer

Differentiated Thyroid Cancer

China, Korea, Republic of, Taiwan, India, Malaysia, Turkey, Canada, Vietnam, Argentina, Brazil, Mexico, United States
Jill M Kolesar
National Cancer Institute (NCI); Novartis

Recruiting

Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma

Metastatic Melanoma | BRAF Gene Mutation

United States
Kafrelsheikh University

Not yet recruiting

Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety. (Isotretinoin)

Covid19 Vaccine
M.D. Anderson Cancer Center

Recruiting

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

Thyroid Gland Anaplastic Carcinoma | Thyroid Gland Squamous Cell Carcinoma

United States
Novartis Pharmaceuticals

Recruiting

Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

Melanoma

China
University of Zurich

Recruiting

Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated With Dabrafenib/ Trametinib +/- Immunotherapy (Nov IIT- Pyrex)

Pyrexia

Switzerland
University Hospital, Essen

Recruiting

Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition (ERRITI)

Metastatic Thyroid Cancer

Germany
National Cancer Institute (NCI)

Recruiting

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

Thyroid Cancer | Anaplastic Thyroid Cancer | BRAF Gene Mutation | BRAF Mutation-Related Tumors

United States
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI); American Lebanese Syrian Associated Charities...

Recruiting

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Low Grade Glioma (LGG) of Brain With BRAF Aberration | High Grade Glioma (HGG) of the Brain With BRAF Aberration | Low Grade Glioma of Brain With Neurofibromatosis Type 1

United States
Centre Leon Berard

Recruiting

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST)

Malignant Solid Tumor

France
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Thyroid Gland Anaplastic Carcinoma | BRAF V600K Mutation Present | BRAF NP_004324.2:p.V600E

United States
Novartis Pharmaceuticals

Recruiting

Pediatric Long-Term Follow-up and Rollover Study

Glioblastoma | Astrocytoma | Anaplastic Astrocytoma | Neurofibromatosis Type 1 | Anaplastic Ganglioglioma | Anaplastic Pleomorphic Xanthoastrocytoma | Ganglioglioma | Pleomorphic Xanthoastrocytoma | Diffuse Astrocytoma | Anaplastic Oligodendroglioma | Pilocytic Astrocytoma | Gangliocytoma | Central Neurocytoma | Oligodendroglioma... and other conditions

United States, Belgium, Spain, Denmark, Germany, Czechia, Italy, Australia, Russian Federation, France, Netherlands, Japan, Canada, Finland, Sweden, United Kingdom, Argentina, Israel, Brazil
National Cancer Institute (NCI)

Recruiting

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Glioblastoma | Malignant Glioma | Anaplastic Astrocytoma | Anaplastic Astrocytoma, Not Otherwise Specified | Anaplastic Ganglioglioma | Anaplastic Pleomorphic Xanthoastrocytoma | WHO Grade 3 Glioma

United States, Puerto Rico
Universitair Ziekenhuis Brussel
University Hospital, Ghent

Recruiting

Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma (COMBI-R2)

Melanoma

Belgium
Massachusetts General Hospital
Novartis; Stand Up To Cancer

Recruiting

Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

Metastatic Colorectal Cancer

United States
Inge Marie Svane

Recruiting

Melanoma Metastasized to the Brain and Steroids (MEMBRAINS)

Malignant Melanoma

Denmark
Novartis Pharmaceuticals

Recruiting

Dabrafenib and/or Trametinib Rollover Study

Melanoma | Solid Tumor | High Grade Glioma | Non Small Cell Lung Cancer | Rare Cancers

Spain, Germany, United States, Argentina, Austria, Denmark, France, Hungary, Netherlands, China, Japan, Thailand
Baodong Qin

Recruiting

Efficacy and Safety of Precision Therapy in Refractory Tumor

Refractory Tumor | Rare Tumor

China
Massachusetts General Hospital
Novartis; Barbara Ann Karmanos Cancer Institute; Multiple Myeloma Research Consortium

Recruiting

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States
The Netherlands Cancer Institute
Bristol-Myers Squibb; Eli Lilly and Company; Bayer; GlaxoSmithKline; Merck Sharp... and other collaborators

Recruiting

The Drug Rediscovery Protocol (DRUP Trial) (DRUP)

Cancer | Neoplasm | Tumors | Neoplasia

Netherlands
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma

United States
National Cancer Institute (NCI)
GlaxoSmithKline; Novartis Pharmaceuticals

Active, not recruiting

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Hematopoietic and Lymphoid Cell Neoplasm | Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable...

United States
Novartis Pharmaceuticals

Active, not recruiting

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i)

Melanoma

Italy, Czechia, Germany, Hungary, Canada, United States, Argentina, Australia, Austria, France, Israel, Russian Federation, Spain, Sweden, United Kingdom, Thailand, Belgium, Brazil, Greece, Switzerland, Mexico, Netherlands, Denmark, C... and more
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Unresectable Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Metastatic Melanoma | Recurrent Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Malignant Solid Neoplasm | Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Institut National de la Santé Et de la Recherche...
Institut Bergonié; Commissariat A L'energie Atomique; Plateforme labellisée Inca... and other collaborators

Active, not recruiting

Molecular Profiling of Advanced Soft-tissue Sarcomas (MULTISARC)

Soft Tissue Sarcoma

France
Novartis Pharmaceuticals

Completed

A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma

BRAF V600 Mutation Positive Melanoma

China
Saint Petersburg State University, Russia

Withdrawn

Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer (ANAPLAST-NEO)

Thyroid Gland Anaplastic Carcinoma

Russian Federation

Search clinical trials for: dabrafenib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations